AMGN — AMGEN INC
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 318154 ·
Last close
$421.51
Market Cap
$227.88B
52W High
$447.03
52W Low
$275.36
ADV30
2,908,498
Next earnings
2026-11-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 10,054,000,000 | 7,243,000,000 | 3,514,000,000 | 2,375,000,000 | 95,639,000,000 | 13,989,000,000 | 83,951,000,000 |
| Mar 2026 | 8,618,000,000 | 5,874,000,000 | 2,666,000,000 | 1,819,000,000 | 92,504,000,000 | 12,038,000,000 | 83,314,000,000 |
| Dec 2025 | 9,866,000,000 | 6,890,000,000 | 2,720,000,000 | 1,333,000,000 | 90,586,000,000 | 9,129,000,000 | 81,928,000,000 |
| Sep 2025 | 9,557,000,000 | 6,475,000,000 | 2,526,000,000 | 3,216,000,000 | 90,141,000,000 | 9,445,000,000 | 80,522,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$10,756,000,000
Investing CF
$-2,212,000,000
Financing CF
$-5,316,000,000
CapEx
$-2,159,000,000
Dividends Paid
$-5,203,000,000
Buybacks
—
EPS Diluted TTM
$14.37
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-22,275,000,000
Inventory
$6,220,000,000
Receivables
$10,227,000,000
ST Investments
—
EBIT TTM
$12,955,000,000
Pretax Income TTM
$10,287,000,000
Interest Exp TTM
$2,668,000,000
Analysts
29
Yahoo Snapshot (yfinance, live)
Total Revenue
$38,094,999,552
EBITDA
$17,268,000,768
Free Cash Flow
$8,645,624,832
Enterprise Value
$247,322,492,928
Total Cash
$13,989,000,192
Total Debt
$57,303,998,464
Shares Out
540,632,005
Trailing EPS
$16.11
Book Value
$21.62
ROE
91.5%
ROA
8.7%
Div Yield
2.64%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 36,751,000,000 | 9,080,000,000 | 7,711,000,000 | 90,586,000,000 | 81,928,000,000 | 8,658,000,000 | 9,958,000,000 |
| Dec 2024 | 33,424,000,000 | 7,258,000,000 | 4,090,000,000 | 91,839,000,000 | 85,962,000,000 | 5,877,000,000 | 11,490,000,000 |
| Dec 2023 | 28,190,000,000 | 7,897,000,000 | 6,717,000,000 | 97,154,000,000 | 90,922,000,000 | 6,232,000,000 | 8,471,000,000 |
| Dec 2022 | 26,323,000,000 | 9,566,000,000 | 6,552,000,000 | 65,121,000,000 | 61,460,000,000 | 3,661,000,000 | 9,721,000,000 |
TTM Snapshot
Revenues TTM
$30,207,000,000
NetIncome TTM
$8,433,000,000
OpCashFlow TTM
$0
Assets (Latest)
$90,586,000,000
Forward EPS
$24.40
Max Pain — expiry 2026-10-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $460.00 · spot: $421.51 · call volume: 3,647 · put volume: 27,015
Expected Move to 2026-10-16:
±$17.75
(4.21%) —
implied range
$403.76 –
$439.26
· ATM straddle on $420.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GILD | GILEAD SCIENCES, INC. | $184.82B | $149.05 | — |
| MRNA | Moderna, Inc. | $76.88B | $192.57 | — |
| ARGX | ARGENX SE | $59.63B | $958.91 | — |
| RVMD | Revolution Medicines, Inc. | $43.99B | $205.26 | — |
| BIIB | BIOGEN INC. | $33.37B | $225.88 | — |
News headlines (Yahoo Finance, 1h cache)
Recombinant Proteins Market - Global Strategic Business Report: Sales Hit to $5.8 Billion by 2030 - Benchmark Thermo Fisher Scientific, Merck KGaA, Amgen, Bio-Techne and GenScript Biotech Amid Tariff
2026-09-30 13:30 · Yahoo
Why Amgen’s 6% Dividend Raise Masks a Tougher Road Ahead
2026-09-29 13:03 · Yahoo
Amgen (AMGN) Has a New Growth Opportunity. But How Much Is It Really Worth?
2026-09-29 01:27 · Yahoo
Take the Zacks Approach to Beat the Markets: Bloom Energy, Microsoft & Amgen in Focus
2026-09-28 12:12 · Yahoo
Why Amgen’s Pipeline Just Got More Interesting
2026-09-27 20:34 · Yahoo
Amgen (AMGN) Sells its Deerfield Campus for $151 Million and Leases it Back
2026-09-27 19:55 · Yahoo
Amgen’s Deerfield office campus sold to Mesirow for $151M in sale-leaseback deal
2026-09-25 22:00 · Yahoo
Amgen (AMGN) Rises Higher Than Market: Key Facts
2026-09-25 20:50 · Yahoo
Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know
2026-09-25 12:00 · Yahoo
Can Roche’s Latest Obesity Drug Results Help it Challenge Eli Lilly and Novo Nordisk?
2026-09-28 19:55 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.